Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.07/Share

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.07), versus (GBP0.08) reported last year.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• MasTec to acquire The Superior Group for about $1.65 billion
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance